Investigational drug · Phase 2
STI-6129
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "STI-6129"
First trial start
2023
Feb 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STI-6129", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "STI-6129" as an intervention, largest first.
Zhejiang ACEA Pharmaceutical Co. Ltd.Industry
NCT05565807 · 84 participants (planned) · Start Feb 9, 2023 · Primary completion Dec 31, 2026
Drug: STI-6129 · For: Relapsed or Refractory Multiple Myeloma
Sites: Beijing, China; Guangzhou, China; Hangzhou, China · 4 sites in all
- Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaStatus unknown
Sorrento Therapeutics, Inc.Industry
NCT05308225 · 72 participants · Start Feb 1, 2023 · Primary completion Dec 2025
Drug: STI-6129 · For: Multiple Myeloma
Sites: New York, New York; Canton, Ohio · 3 sites in all
- Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisStatus unknown
Sorrento Therapeutics, Inc.Industry
NCT04316442 · 60 participants (planned) · Start Apr 1, 2021 · Primary completion Sep 2024
Drug: STI-6129 · For: Light Chain (AL) Amyloidosis
Sites: Duarte, California; Boston, Massachusetts; Detroit, Michigan · 4 sites in all
Sorrento Therapeutics, Inc.Industry
NCT05584709 · 34 participants (planned) · Start Mar 2023 · Primary completion Aug 2025
Drug: STI-6129 · For: Advanced Solid Tumor
Sites: New York, New York
Sorrento Therapeutics, Inc.Industry
NCT05692908 · 0 participants · Start Sep 2023 · Primary completion Sep 2024
Drug: STI-6129 · For: Light Chain (AL) Amyloidosis
- STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawn
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05519527 · 0 participants · Start Aug 16, 2022 · Primary completion Feb 15, 2023
Drug: Part 1 (STI-6129); Part 2 (STI-6129) · For: Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed or Refractory Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- QLS32015Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Relapsed or Refractory Multiple Myeloma
- QLS4131Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma
- MBS314Phase 22 trials
Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma
- AZD4045Phase 21 trial
AstraZeneca · Relapsed or Refractory Multiple Myeloma
- CD38Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.